Trials / Unknown
UnknownNCT04627584
A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of MW33 Injection to Evaluate the Efficacy and Safety in Patients With Mild or Moderate COVID-19
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the clinical efficacy and safety of MW33 injection in patients with mild or moderate COVID-19, and to evaluate its pharmacokinetic profile and immunogenicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | MW33 injection | a recombinant fully human antibody to coronavirus |
| COMBINATION_PRODUCT | MW33 injection placebo | Placebo |
Timeline
- Start date
- 2020-12-29
- Primary completion
- 2021-05-01
- Completion
- 2021-09-01
- First posted
- 2020-11-13
- Last updated
- 2021-02-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04627584. Inclusion in this directory is not an endorsement.